reducing angina frequency and improving exercise performance in patients with chronic angina. [13] [14] [15] [16] The large-scale, placebo-controlled randomized Ranolazine in Patients with Incomplete Revascularization After Percutaneous Coronary Intervention (RIVER-PCI) trial was designed to evaluate the efficacy of ranolazine as an adjunct to standard medical therapy in patients with incomplete revascularization (ICR) following PCI. The main results of RIVER-PCI revealed that ranolazine compared with placebo did not reduce the primary composite end point of ischemia-driven rehospitalization or revascularization after a median follow-up of 643 days (26.2% versus 28.3% respectively; HR 0.95; 95% CI 0.82-1.10). 17 The ischemia-driven definition included angina with or without documented ischemia, or angina-equivalent with documented ischemia, and ischemia could be documented by ECG changes, imaging, or biomarker elevation. No significant differences were seen between groups in components of the primary or secondary endpoints, and results were consistent across multiple subgroups. In this manuscript, we report the results of the RIVER-PCI integrated QOL study which was designed to supplement and inform trial clinical endpoints with patient-reported angina and QOL.
Methods
RIVER-PCI was a multicenter, randomized, double-blind, placebocontrolled trial conducted at 245 centers in 15 countries. The design and rationale of the RIVER-PCI trial have been previously reported. 18 Briefly, participants with a history of chronic angina who underwent PCI with consequent ICR were randomized to 1000 mg of ranolazine twice a day, or matching placebo. ICR was defined as the presence of at least one lesion with visually estimated ≥50% diameter stenosis in a coronary artery with reference vessel diameter ≥2.0 mm, whether in a PCI-treated target vessel or in a nontreated nontarget vessel. For post-CABG patients, ICR was defined as the presence of one or more lesions with visually estimated ≥50% diameter stenosis in a nonbypassed epicardial vessel ≥2.0 mm in diameter, or at least one visually estimated ≥50% diameter stenosis in a bypass graft supplying an otherwise nonrevascularized myocardial territory. History of chronic angina was defined as ≥2 episodes of anginal pain or discomfort in the chest, jaw, shoulder, back, neck, or arm precipitated by exertional or emotional stress, and relieved by rest or sublingual nitroglycerin, occurring on ≥2 separate days between 30 days and 1 year prior to PCI. Patients could also have additional angina in the 30 days prior to PCI, and could have an acute coronary syndrome (ACS) indication for their qualifying PCI. The primary end point of RIVER-PCI was the composite rate of ischemia-driven revascularization or hospitalization. The ethics committee at each participating center approved the protocol, and all patients provided written informed consent.
QOL Population
RIVER-PCI randomized 2651 patients; of these, 2604 with a qualifying PCI who received at least one dose of study drug were included in the full efficacy analysis set. For the QOL analysis, we excluded another 215 patients (8.3%) at eight sites with missing or invalid QOL questionnaires. After these exclusions, the final QOL intentionto-treat population included 2389 patients; of these, 1207 were randomized to ranolazine and 1182 were randomized to placebo ( Figure  I in the online-only Data Supplement).
Health Status and QOL
Using a select group of instruments, disease-specific health status and QOL indicators were collected at baseline, 1 month, 6 months, and 12 months, as well as at end of treatment, when applicable (ie, end of treatment was a visit for subjects withdrawing from the study prior to month 12). Participants received a copy of the survey translated into their native language at the beginning of each study visit, and responses were entered into the case report form by the coordinator. Study visits were attended at all four QOL time points in 78.1% of patients (n=1866), three time points in 12.5% (n=298), and two time points in 5.2% (n=125). Baseline characteristics were compared between participants with complete and incomplete QOL data, where complete data were defined as an available score on each of the three key endpoints at all four time points. Age, sex, baseline functional status, and regional differences were noted, although the baseline Seattle Angina Questionnaire (SAQ) Angina Frequency and Treatment Satisfaction reports were evenly balanced across arms (Table I in the online-only Data Supplement).
The primary end point of the QOL substudy was improvement in the average SAQ angina frequency score over the 1 year from baseline to 12 months; key secondary QOL endpoints included SAQ Treatment Satisfaction, and Duke Activity Status Index (DASI) scores. The SAQ angina frequency domain is validated, correlates well with daily angina logs, and is the primary SAQ domain showing responsiveness to treatment with ranolazine in clinical trial populations. 14, 19, 20 The SAQ includes five domains: angina frequency, angina stability, angina-related treatment satisfaction, angina-related physical function, and QOL. 21, 22 Each SAQ domain is scored separately from 0 to 100, with higher scores indicating better health status. Based on prior work, 23 SAQ angina frequency scores were categorized for descriptive purposes as no angina (SAQ score=100), monthly angina (SAQ score=61-99), weekly angina (SAQ score=31-60), and daily angina (SAQ score=0-30). The 12-item DASI focuses on physical activity ranging from self-care to strenuous physical work. 24 Each activity is weighted by the metabolic output associated with its performance, and a final score weights the performed activities. DASI scores range from 0 (worst) to 58.2 (best). Secondary endpoints included: modified SAQ angina stability, SAQ physical function, SAQ QOL, European QOL Five Dimension Three-Level Scale (EuroQol-5D-3 L; a 5-item instrument assessing specific domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), 25 Rose Dyspnea Scale, and the five-question Mental Health Inventory (MHI-5) from the 36-item Short Form Health Survey (SF-36) version 2.0.
26,27

Analysis
Descriptive statistics are summarized by treatment group as means and standard deviations for continuous variables, and counts and percentages for categorical variables. Baseline characteristics were compared between the two treatment groups using the Wilcoxon rank sum test for continuous variables and Pearson's chi-squared test for categorical variables. Also using Pearson's chi-squared test, we compared post-baseline characteristics of interest such as discontinuation of study treatment, change in number of anti-ischemic medications, repeat revascularization, and subjects' belief about treatment arm at month 12, as well as concomitant medication use at baseline and month 12.
The SAQ, DASI, MHI-5, and EuroQol-5D-3 L endpoints were analyzed using an adjusted repeated measures mixed model with month 1, 6, and 12 responses serving as outcome variables. The adjusted model included terms for baseline score, reason for qualifying PCI (ACS or non-ACS indication), history of type 1 or 2 diabetes mellitus, treatment, visit, and treatment-by-visit interaction using an unstructured covariance matrix. Least squares means and 95% confidence intervals (CIs) were generated for treatment groups and treatment group mean differences (ranolazine minus placebo) at each time point, as well as the average across time. Restricted maximum likelihood estimation was used to model all available data from each patient without imputing missing values or excluding patients with missing data from the analysis. 28, 29 This type of analysis provides unbiased estimates when the reason for missing data can be ignored, as when unobserved variables do not explain the probability of missingness over and above what is explained by observed variables. Nevertheless, we also performed a sensitivity analysis of the primary endpoints using a multiple imputation approach to assess the impact of missing data. The multiple imputation model included baseline, by guest on April 8, 2017 http://circ.ahajournals.org/ Downloaded from month 1, month 6, and month 12 scores together, plus the reason for index PCI, DM, age, sex, and treatment group. The repeated measures mixed model was also used to compare the treatment effect on the key endpoints within the following subgroups of interest: age, sex, ACS indication for index PCI, anti-anginal medication use at baseline, diabetes mellitus, and angina frequency at baseline. Treatment by subgroup interaction terms were tested at each time point. The Rose Dyspnea Scale was compared by treatment group at each time point using the Wilcoxon rank sum test, with missing data due to adjudicated cardiovascular death imputed as the worst possible value.
All of the inferential comparisons were conducted in the QOL population as intention-to-treat using two-sided tests at a nominal significance level of 0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
Results
Baseline characteristics were generally balanced between arms (Table 1) . However, for two important characteristics, there were more patients in the ranolazine arm that had more prior revascularization (P=0.04) and more daily or weekly angina (SAQ angina frequency ≤60; P=0.004). Overall, nearly 60% of the population had monthly or less frequent angina at baseline based on the SAQ angina frequency score, with 15% of ranolazine and 17% of placebo patients reporting no angina. At baseline, patients in both arms were well treated, with high usage rates of aspirin (≈95%), β-blockers (≈86%), angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (≈79%), and statins (≈93%; Table II in the onlineonly Data Supplement). These rates of secondary prevention were similarly high in both arms at month 12. In addition, concomitant use of anti-ischemic medications was common, with 92% of patients on at least 1 anti-ischemic medication at baseline or at 12-month follow-up, and nearly one-third of patients on two or more anti-ischemic medications at both time points 
SAQ Angina Frequency
The observed means and standard deviations at baseline, month 1, and month 12 are shown by treatment group in Table 2 . The SAQ angina frequency and SAQ angina stability scores were slightly worse at baseline in the ranolazine group compared to placebo (P=0.014); all other health status and QOL scores were balanced at baseline. The responses at month 1 improved from baseline in both arms following index PCI (P<0.001) and responses at month 6 and month 12 were similar between arms ( Table 2 ). The mean SAQ angina frequency score at baseline (67.3 ranolazine and 69.7 placebo) was substantially improved by month 1 in both arms (86.6 ranolazine and 85.8 placebo; Figure 1A ). SAQ angina frequency improvements persisted in both treatment arms at months 6 and 12. In the adjusted repeated measures analysis, there was a numerically higher score with ranolazine in SAQ angina frequency at month 1 (least squares mean difference 1.4; 95% CI -0.1, 2.8; P=0.06), and there were no significant differences between treatment groups at month 6 or month 12 ( Figure 1B) . Likewise, the least squares mean difference (ranolazine minus placebo) average across time was not significant (1.0; 95% CI -0.2, 2.2; P=0.11). Sensitivity analyses imputing missing data generated similar findings (data not shown).
Prespecified QOL subgroups
SAQ angina frequency across treatment groups did not differ by age, sex, indication for qualifying PCI, or baseline anti-anginal use; however, significant improvements over time with ranolazine were observed in patients with diabetes mellitus (least squares mean difference 2.7; 95% CI 0.5, 4.9; P=0.02) and those with daily or weekly angina at baseline (least squares mean difference 2.3; 95% CI 0.0, 4.6; P=0.048; Table 3 ). For the diabetes mellitus and daily or weekly baseline angina subgroups, treatment differences in SAQ angina frequency were statistically significant at month 6 (mean difference 3.3; 95% CI 0.6, 6.1; P=0.02 and mean difference 3.4; 95% CI 0.6, 6.2; P=0.02, respectively). These time points also had significant subgroup by treatment interaction terms: diabetes mellitus by treatment (P=0.03) and daily or weekly baseline angina by treatment (P=0.01; Figure 2 ). These differences were not statistically significant at month 1 or month 12.
Disease-Related Health Status and QOL
There were no significant differences overall in the two key secondary QOL endpoints: SAQ treatment satisfaction (least No significant differences were observed in the diabetic subgroup for SAQ treatment satisfaction. No significant differences in DASI or SAQ treatment satisfaction were observed for patients with more frequent baseline angina. We observed similar improvement post baseline in other health status and QOL measures including SAQ physical limitation, SAQ angina stability, SAQ QOL, DASI, MHI-5, EuroQol-5D-3 L, and Rose Dyspnea Scale, with no differences across treatment arms over time ( Table 2) .
Discussion
The QOL analysis was designed to test the hypothesis that improvement in angina symptoms with ranolazine would result in less ischemia-driven rehospitalizations or revascularizations over time in patients with a history of chronic angina who had ICR following PCI, which would in turn improve quality of life. As previously reported, ICR details revealed that almost half of these patients had three-vessel disease and one-third had an untreated chronic total occlusion, with a mean SYNTAX score of approximately 10.5 in each arm post-PCI. 17 Consistent with the neutral clinical results of RIVER-PCI, our analysis also found that quality of life and angina frequency over time were no different with ranolazine compared to placebo in this population. Many patients had monthly or no angina at baseline, and angina frequency was substantially improved in both arms following the qualifying PCI (despite the presence of ICR), leaving a low burden of angina during follow-up as seen by subsequent SAQ scores. Other disease-related health status and QOL scores were similarly improved at all follow-up time points for both arms. Therefore, a strategy of adding ranolazine to standard therapy in patients with a history of chronic angina who had ICR post-PCI, as studied in RIVER-PCI, did not show an incremental benefit beyond that realized by index PCI. These results are not entirely surprising, given the low angina burden during follow-up.
Recurrent angina is a critical criterion for those likely to benefit from long-term treatment with ranolazine. Recurrent angina occurs in 20% to 60% of patients one-year following PCI depending on assessment method, study population, and era of reporting. [30] [31] [32] Frequent angina is a strong predictor of recurrent angina despite medical treatment or revascularization in cardiovascular populations. 5 While the incidence of baseline angina in RIVER-PCI (SAQ angina frequency = 68. 5 7, 8, 14, 20, 33 The latter populations with more frequent angina at baseline were those in which ranolazine demonstrated long-term efficacy. Overall, in RIVER-PCI there was no improvement in SAQ angina frequency with ranolazine compared with placebo (mean difference = 1.0) beyond the improvement realized from index PCI in both arms.
While ICR following PCI was an inclusion criteria for RIVER-PCI, definitive measures of associated ischemia (ie, fractional flow reserve or stress testing) were not required. Given lack of ischemia confirmation, as well as the weak correlation between ischemia and angina, 34 the presence of ICR may or may not have contributed to recurrent angina or ischemia-driven clinical endpoints in this study. The primary end point occurred in nearly 27% of RIVER-PCI patients during follow-up, yet in clinical practice these repeat ischemia-driven hospitalizations or revascularizations are often in response to findings other than angina. 35 In clinical practice, revascularization is also often pursued without attempting titration of anti-ischemic medical therapy. 36 This tendency may be enhanced among a population with documented ICR in the year following PCI.
The population enrolled in RIVER-PCI was typical for patients who have PCI, as they were older, male, and had diabetes mellitus with little heart failure. Those with both angina and ischemia in The Prospective Observational Longitudinal Registry of Patients with Stable Coronary Artery Disease (CLARIFY) population were more frequently younger, female, with heart failure, and diabetes mellitus than those with either angina or ischemia alone. 37 Symptoms of angina may arise from obstructive coronary disease (including ICR following PCI), microvascular dysfunction, or a mismatch in supply and demand, all with varying degrees of associated ischemia. Therefore, targeting a population with angina that is reflective of ischemia in the absence of confirmative diagnostic tests, is an important challenge (as well as limitation) for chronic studies evaluating ICR.
The RIVER-PCI population was largely asymptomatic following the index PCI. Angina is a transient condition for most, and the inclusion requirement for chronic angina required only two episodes over the prior year. Therefore, the asymptomatic pattern in follow-up was less surprising. The comparisons between baseline and follow-up angina was also confounded by an effective competing baseline intervention for angina in both arms. Some have suggested that ICR contributes to major adverse cardiac events and repeat revascularization following PCI as compared with CABG. 11 Nevertheless, substantial improvements in angina following index PCI raise questions about the symptomatic significance of ICR in this population. Angiographic details of ICR within the RIVER-PCI population have been previously detailed, including a number of chronic occlusions or lesions in small vessels 17 ; the extent of ischemia from these lesions was not assessed. The RIVER-PCI population also had relatively few subsequent revascularizations or changes to anti-anginal medications in either arm, which is consistent with the population's good overall health status and supports the limited ability to demonstrate an incremental effect of any additional anti-angina therapy in this setting. Despite these findings, the rate of ischemia-driven hospitalization or revascularization during follow-up was high and similar to that predicted from prior studies. 9, 10 These events are known to affect QOL and increase healthcare resource consumption, thereby demonstrating the need for additional approaches to improve outcomes in this population. 38, 39 Our study included patients with ACS, so in some cases, baseline angina frequency may have been due to a thrombotic process (although we did require chronic angina >30 days prior to admission). Furthermore, there were no differences across arms in SAQ angina frequency over time in patients with or without an initial ACS. In the MERLIN-TIMI 36 trial, an ACS population with prior angina benefitted from ranolazine regardless of PCI, 16, 40 which was not confirmed in the ACS cohort of RIVER-PCI. Yet only 25% of the MERLIN-TIMI 36 prior angina cohort underwent a PCI during index hospitalization, so more baseline angina and a lower rate of PCI in the MERLIN-TIMI 36 cohort (with less effective angina relief) may have contributed to the ranolazine benefit over time.
For the prespecified subgroups, no significant improvement was noted among women, the elderly, and those with an ACS indication for PCI. However, a marginally favorable effect of ranolazine was observed in two subgroups: diabetics and those with more frequent baseline angina. The effect of ranolazine in patients with more frequent angina is expected since angina is a predictor of recurrent angina, regardless of revascularization. 5 The cohort with more baseline angina (SAQ angina frequency ≤60, mean difference = 2.3) had improvements similar to that seen in the MERLIN-TIMI 36 prior angina cohort (mean difference = 3.4) and the TERISA population (mean difference = 2.8). 33 These studies suggest in aggregate that ranolazine may have higher efficacy in the setting of higher angina frequency (measured via the SAQ). Similarly, the effect of ranolazine †The baseline n for subgroups are noted in Table 1 and Table III in the online-only Data Supplement. ‡Antiangina meds = long-acting nitrates, β-blockers, and calcium channel blockers.
by guest on April 8, 2017 http://circ.ahajournals.org/ Downloaded from among diabetics was also previously demonstrated in the MERLIN-TIMI 36 and TERISA trials. 14, 33, 41 In subgroups that demonstrated mean differences across the treatment arm favoring ranolazine, treatment improvement and interactions were only significant at month 6, which could be due to the recurrence of angina at this time, or to the play of chance. In addition, ranolazine was discontinued more often than placebo by month 6 due to more adverse events, possibly lessening the effects of ranolazine at longer follow-up intervals. Angina improves over time regardless of treatment, 5, 14 which dilutes the discernibility of differences at the later time point. Conversely, angina improvement at month 1 is driven by a PCI treatment effect, whereas angina improvement at month 6 may be more consistent with a ranolazine effect, particularly among patient subgroups most likely to benefit from this medication.
Limitations
Our study had several limitations. First, there was no confirmation of ischemia prior to the index PCI or immediately following PCI in patients showing angiographic evidence of ICR. Second, some qualifying angina may have been noncardiac in origin. Third, angina was assessed at discrete time points; interval symptoms, including those prior to repeat revascularization or hospitalization, were not assessed. Fourth, the high rate of study drug discontinuation (greater with ranolazine than placebo) may have limited the ability to explore treatment effects over longer follow-up intervals. Fifth, most patients were on 1 to 2 additional anti-anginal medications (ie, long-acting nitrates, β-blockers, or calcium channel blockers), perhaps diminishing ranolazine's potential effect on improving SAQ angina frequency and QOL with an already low angina burden post PCI. This being said, no differential treatment effect was evident in patients on 0 to 1 versus 2 to 3 baseline anti-anginal medications. Sixth, due to angiographic lesions deemed unsuitable for PCI, all patients had ICR. As a result, this study does not include patients with chronic angina and revascularizable disease, nor does it include patients with angina who did not have significant epicardial coronary artery disease. Seventh, the exclusion of the 215 patients from 8 sites with missing or invalid questionnaires may have altered our findings, although this was done prior to analysis and was based on lack of participation or concern for validity of the data. Finally, significance testing of multiple health status scales raises concerns about the interpretation of any single p-value; however, findings of significance in this study were only noted for scales and subgroups that were prespecified.
Conclusions
Despite angiographic ICR following PCI, there was no incremental benefit in adding ranolazine. Our findings highlight the difficulty in assessing the clinical significance of ICR, since patient-reported angina and QOL markedly improved within 1 month after PCI. RIVER-PCI clarifies that prescribing ranolazine based on angiographic determinations alone is unsupported, despite a high rate of recurrent events in this population over time.
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